Inventor
Le Wang
Inventor
Vernon Hills, IL, US
Overview
Patents· 50 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds32%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
A61KPreparations for medical, dental or toiletry purposes23%
C07CAcyclic or carbocyclic compounds3%
Y02ATechnologies for adaptation to climate change3%
C07BGeneral methods of organic chemistry2%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%
A01HNew plants or non-transgenic processes for obtaining them1%
C08BPolysaccharides1%
C12NMicroorganisms or enzymes1%
PatentTitleYear
10,633,379Bromodomain inhibitors202010,336,931Use of dual-cation fluorocarbon surfactant as amphiphobic wettability reversal agent in drilling fluid201910,131,657Bromodomain inhibitors201810,085,985Bromodomain inhibitors201810,035,800Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors20189,994,581Bromodomain inhibitors20189,957,263Bromodomain inhibitors20189,877,958'Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases'20189,844,547Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases20179,776,990'Isoindolone derivatives'20179,561,231'Pyridinone and pyridazinone derivatives'20179,428,514'Bromodomain inhibitors'20169,359,296'7-substituted indole Mcl-1 inhibitors'20169,321,764'Dihydro-pyrrolopyridinone inhibitors'20169,303,025'Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases'20169,296,741'Bromodomain inhibitors'20169,266,877'Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases'20169,227,963'Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases'20169,174,982'Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases'20159,125,913'Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases'20159,073,855'BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases'20159,072,748'BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases'20159,045,420'Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases'20159,035,047'7-substituted indole Mcl-1 inhibitors'20159,034,875'Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases'20159,029,404'Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases'20158,980,879'Bromodomain inhibitors'20158,952,157'Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases'20158,940,737'Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases'20158,889,675'Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases'20148,586,754'BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases'20138,580,794'Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases'20138,563,735'Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases'20138,557,983'Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases'20138,546,399'Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases'20138,445,679'7-substituted indole MCL-1 inhibitors'20138,232,273'Heterocyclic compounds and methods of use'20128,148,384'Substituted thieno[3,2-d]pyrimidine PIM kinase inhibitors as cancer chemotherapeutics'20127,956,185'Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases'20117,456,169'Heterocyclic kinase inhibitors'20087,323,570'Farnesyltransferase inhibitors'20087,211,595'Farnesyltransferase inhibitors'20077,163,939'Macrocyclic kinase inhibitors'20076,310,095'Inhibitors of protein isoprenyl transferases'20016,228,868'Oxazoline antiproliferative agents'20016,221,865'Inhibitors of protein isoprenyl transferases'20016,204,293'Inhibitors of protein isoprenyl transferases'20016,201,001'Imidazole antiproliferative agents'20015,585,544'Method of causing somatic hybridization between two species of algae'19965,365,018'Method of causing somatic hybridization between two species of algae'1994Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1994–1996Based in Boston, MA, US· patent location history
2001–2012Patents assigned to ABBOTT LAB (9)· patent assignee history
2001–2008Based in Mundelein, IL, US· patent location history
2007–2020Based in Vernon Hills, IL, US· patent location history
2012–2013Patents assigned to TAO ZHI-FU (8)· patent assignee history
2012–2013Patents assigned to WANG LE (8)· patent assignee history
2012–2013Patents assigned to ELMORE STEVEN W (6)· patent assignee history
2013–2020Patents assigned to ABBVIE INC (35)· patent assignee history
2019Based in Beijing, CN· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ABBVIE INC | 35 | 2013–2020 |
| ABBOTT LAB | 9 | 2001–2012 |
| TAO ZHI-FU | 8 | 2012–2013 |
| WANG LEself | 8 | 2012–2013 |
| ELMORE STEVEN W | 6 | 2012–2013 |
Locations
| Location | Patents | Span |
|---|---|---|
| Vernon Hills, Illinois, US | 39 | 2007–2020 |
| Mundelein, Illinois, US | 8 | 2001–2008 |
| Boston, Massachusetts, US | 2 | 1994–1996 |
| Beijing, CN | 1 | 2019 |